Back to results
US 2021/0276955 A1Published application
Deuterated compounds as immunomodulators
AssigneeChemoCentryx, Inc.
InventorsPingchen FAN, Rebecca M. LUI, Venkat Reddy MALI, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
Life of this patent
Estimating the term…
Abstract
Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Claims19
A compound of Formula (I)
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from the group consisting of CH3, CH2D, CHD2, and CD3, and CD2OH;
- R2 is selected from the group consisting of CH3, CH2D, CHD2, CD3, CH2OH, CDHOH, and CD2OH;
- R3 is H or D;
- R4 is H or D;
- m is an integer from 0-6;
- n is an integer from 0-3;
- o is an integer from 0-4;
- p is an integer from 0-9;
- and
- q is an integer from 0-3;
- and wherein said compound has at least one deuterium atom present in an amount of at least 80%.
9 more elements
(canceled)
Dependencies are inferred from the claim text.